Home Cart Sign in  
Chemical Structure| 174671-46-6 Chemical Structure| 174671-46-6

Structure of Tavaborole
CAS No.: 174671-46-6

Chemical Structure| 174671-46-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AN-2690 is a broad-spectrum antifungal agent used to treat onychomycosis.

Synonyms: AN-2690

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Brett H. Pogostin ; Samuel X. Wu ; Michael J. Swierczynski ; Christopher Pennington ; Si-Yang Li ; Dilrasbonu Vohidova , et al.

Abstract: Maintaining safe and potent pharmaceutical drug levels is often challenging. Multidomain peptides (MDPs) assemble into supramolecular hydrogels with a well-defined, highly porous nanostructure that makes them attractive for drug delivery, yet their ability to extend release is typically limited by rapid drug diffusion. To overcome this challenge, we developed self-assembling boronate ester release (SABER) MDPs capable of engaging in dynamic covalent bonding with payloads containing boronic acids (BAs). As examples, we demonstrate that SABER hydrogels can prolong the release of five BA-containing small-molecule drugs as well as BA-modified insulin and antibodies. Pharmacokinetic studies revealed that SABER hydrogels extended the therapeutic effect of ganfeborole from days to weeks, preventing Mycobacterium tuberculosis growth better than repeated oral administration in an infection model. Similarly, SABER hydrogels extended insulin activity, maintaining normoglycemia for six days in diabetic mice after a single injection. These results suggest that SABER hydrogels present broad potential for clinical translation.

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of Tavaborole

CAS No. :174671-46-6
Formula : C7H6BFO2
M.W : 151.93
SMILES Code : OB1OCC2=CC(F)=CC=C12
Synonyms :
AN-2690
MDL No. :MFCD10699483
InChI Key :LFQDNHWZDQTITF-UHFFFAOYSA-N
Pubchem ID :11499245

Safety of Tavaborole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Candida albicans 4 to >16 μg/ml 24 hours Evaluated the in vitro antifungal activity of Tavaborole against Candida albicans, showing MIC range of 4 to 16 μg/ml, indicating low activity. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01632-18
Candida tropicalis 8 to >16 μg/ml 24 hours Evaluated the in vitro antifungal activity of Tavaborole against Candida tropicalis, showing MIC50 of 16 μg/ml and MIC90 of 16 μg/ml, indicating low activity. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01632-18
Candida parapsilosis 2 to >16 μg/ml 24 hours Evaluated the in vitro antifungal activity of Tavaborole against Candida parapsilosis, showing MIC50 of 16 μg/ml and MIC90 of 16 μg/ml, indicating low activity. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01632-18
Escherichia coli Y9633 4 µg/ml 24 hours Evaluate the growth inhibitory effect of Tavaborole on E. coli Y9633, results showed that Tavaborole significantly inhibited bacterial growth at 4 µg/ml. AMB Express. 2022 Dec 1;12(1):151
Escherichia coli ATCC 25922 4 µg/ml 24 hours Evaluate the growth inhibitory effect of Tavaborole on E. coli ATCC 25922, results showed that Tavaborole significantly inhibited bacterial growth at 4 µg/ml. AMB Express. 2022 Dec 1;12(1):151
Aspergillus flavus 0.5 to 16 μg/ml 48 hours Evaluated the in vitro antifungal activity of Tavaborole against Aspergillus flavus, showing MIC50 of 2 μg/ml and MIC90 of 4 μg/ml, indicating low activity. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01632-18
Escherichia coli 4 μg/mL (MIC) 8 days Test the frequency and mechanism of tavaborole resistance evolution in E. coli, finding resistance primarily caused by mutations in the leuS gene Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17924-17931
Trichophyton rubrum 8 to 16 μg/ml 96 hours Evaluated the in vitro antifungal activity of Tavaborole against Trichophyton rubrum, showing MIC range of 8 to 16 μg/ml, indicating low activity. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01632-18

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Intraperitoneal infection model Intraperitoneal injection 16 mg/kg or 32 mg/kg Single dose, observed for 7 days Evaluate the in vivo efficacy of tavaborole in combination with meropenem EBioMedicine. 2025 Jun;116:105754
Female ICR mice Peritonitis infection model Intraperitoneal injection 20 mg/kg Single dose, lasted for 24 hours Evaluate the therapeutic effect of Tavaborole combined with Tobramycin on MDR E. coli Y9633 infection, results showed that the combination significantly reduced bacterial load and improved survival rate. AMB Express. 2022 Dec 1;12(1):151

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.58mL

1.32mL

0.66mL

32.91mL

6.58mL

3.29mL

65.82mL

13.16mL

6.58mL

References

 

Historical Records

Categories